Other research analysts also recently issued research reports about the stock. SVB Leerink restated a market perform rating and set a $19.00 price objective on shares of Amicus Therapeutics in a report on Tuesday, May 19th. JPMorgan Chase & Co. restated a buy rating on shares of Amicus Therapeutics in a report on Monday, June 8th. HC Wainwright restated a buy rating and set a $20.00 price objective on shares of Amicus Therapeutics in a report on Tuesday, June 16th. Chardan Capital restated a hold rating and set a $12.50 price objective on shares of Amicus Therapeutics in a report on Saturday, May 9th. Finally, BTIG Research started coverage on shares of Amicus Therapeutics in a report on Tuesday, June 16th. They issued a buy rating and a $19.00 target price for the company. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $19.08.
Amicus Therapeutics stock opened at $15.54 on Tuesday. The company has a quick ratio of 4.31, a current ratio of 4.45 and a debt-to-equity ratio of 0.50. Amicus Therapeutics has a 12-month low of $6.25 and a 12-month high of $15.91. The firm’s fifty day moving average is $12.91 and its 200 day moving average is $10.72. The company has a market capitalization of $3.93 billion, a PE ratio of -11.95 and a beta of 1.29.
Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.07). Amicus Therapeutics had a negative return on equity of 63.24% and a negative net margin of 155.73%. The business had revenue of $60.53 million for the quarter, compared to analyst estimates of $57.21 million. Sell-side analysts expect that Amicus Therapeutics will post -1.06 EPS for the current fiscal year.
In related news, CEO John F. Crowley sold 20,000 shares of the stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $9.92, for a total transaction of $198,400.00. Following the completion of the transaction, the chief executive officer now owns 969,696 shares in the company, valued at $9,619,384.32. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Samantha Prout sold 3,366 shares of the stock in a transaction dated Friday, June 19th. The shares were sold at an average price of $15.00, for a total transaction of $50,490.00. Following the transaction, the insider now owns 20,501 shares of the company’s stock, valued at approximately $307,515. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 139,785 shares of company stock valued at $1,605,821. 2.30% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Pathstone Family Office LLC bought a new position in Amicus Therapeutics during the first quarter valued at about $37,000. Quantbot Technologies LP boosted its position in Amicus Therapeutics by 82.1% during the fourth quarter. Quantbot Technologies LP now owns 9,699 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 4,373 shares during the period. Neo Ivy Capital Management bought a new position in Amicus Therapeutics during the fourth quarter worth about $111,000. C M Bidwell & Associates Ltd. bought a new position in Amicus Therapeutics during the first quarter worth about $109,000. Finally, Ironsides Asset Advisors LLC bought a new position in Amicus Therapeutics during the first quarter worth about $112,000.
About Amicus Therapeutics
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.
Recommended Story: Economic Bubble
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.